Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue.
acetylcholine
exocytosis
hyperkinesis
mouse model
tetrabenazine
vesicular monoamine transport proteins
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
revised:
10
07
2024
received:
04
08
2023
accepted:
23
08
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
Tetrabenazine (TBZ), used for treating hyperkinetic disorders, inhibits vesicular monoamine transporter-2 (VMAT-2), which sequesters monoamines into vesicles for exocytosis. However, our knowledge of the effect of TBZ on monoaminergic transmission is limited. Herein, we provide neurochemical evidence regarding the effect of VMAT-2 inhibition on vesicular neurotransmitter release from the prefrontal cortex (PFC) and striatum (STR) (brain regions involved in characteristic TBZ treatment side effects). The interaction between TBZ and MDMA was also assessed regarding motor behaviour in mice. Vesicular storage capacity and release of [ TBZ lowered the storage capacity and inhibited the vesicular release of [ Our observations provide neurochemical evidence explaining the mechanism of VMAT-2 inhibitors in the brain and support the involvement of dopaminergic and noradrenergic transmission in hyperkinetic movement disorders.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Tetrabenazine (TBZ), used for treating hyperkinetic disorders, inhibits vesicular monoamine transporter-2 (VMAT-2), which sequesters monoamines into vesicles for exocytosis. However, our knowledge of the effect of TBZ on monoaminergic transmission is limited. Herein, we provide neurochemical evidence regarding the effect of VMAT-2 inhibition on vesicular neurotransmitter release from the prefrontal cortex (PFC) and striatum (STR) (brain regions involved in characteristic TBZ treatment side effects). The interaction between TBZ and MDMA was also assessed regarding motor behaviour in mice.
EXPERIMENTAL APPROACH
METHODS
Vesicular storage capacity and release of [
KEY RESULTS
RESULTS
TBZ lowered the storage capacity and inhibited the vesicular release of [
CONCLUSION AND IMPLICATIONS
CONCLUSIONS
Our observations provide neurochemical evidence explaining the mechanism of VMAT-2 inhibitors in the brain and support the involvement of dopaminergic and noradrenergic transmission in hyperkinetic movement disorders.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus
ID : RRF-2.3.1-21-2022-00011
Informations de copyright
© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Abbracchio, M. P., Abraham, G., Agoulnik, A., Alexander, W., Al‐Hosaini, K., Bäck, M., Baker, J. G., Barnes, N. M., … Ye, R. D. (2023). The Concise Guide to PHARMACOLOGY 2023/24: G protein‐coupled receptors. British Journal of Pharmacology, 180, S23–S144. https://doi.org/10.1111/bph.16177
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Amarosi, L., Anderson, C. M. H., Beart, P. M., Broer, S., Dawson, P. A., Gyimesi, G., Hagenbuch, B., Hammond, J. R., Hancox, J. C., … Verri, T. (2023). The Concise Guide to PHARMACOLOGY 2023/24: Transporters. British Journal of Pharmacology, 180, S374–S469. https://doi.org/10.1111/bph.16182
Anne, C., & Gasnier, B. (2014). Vesicular neurotransmitter transporters: Mechanistic aspects. Current Topics in Membranes, 73, 149–174. https://doi.org/10.1016/B978-0-12-800223-0.00003-7
Baranyi, M., Milusheva, E., Vizi, E. S., & Sperlagh, B. (2006). Chromatographic analysis of dopamine metabolism in a Parkinsonian model. Journal of Chromatography. A, 1120(1–2), 13–20. https://doi.org/10.1016/j.chroma.2006.03.018
Bedard, C., Wallman, M. J., Pourcher, E., Gould, P. V., Parent, A., & Parent, M. (2011). Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism & Related Disorders, 17(8), 593–598. https://doi.org/10.1016/j.parkreldis.2011.05.012
Buskila, Y., Breen, P. P., Tapson, J., van Schaik, A., Barton, M., & Morley, J. W. (2014). Extending the viability of acute brain slices. Scientific Reports, 4, 5309. https://doi.org/10.1038/srep05309
Carbon, M., Hsieh, C. H., Kane, J. M., & Correll, C. U. (2017). Tardive dyskinesia prevalence in the period of second‐generation antipsychotic use: A meta‐analysis. The Journal of Clinical Psychiatry, 78(3), e264–e278. https://doi.org/10.4088/JCP.16r10832
Carlsson, A. (1966). Drugs which block the storage of 5‐hydroxytryptamine and related amines. In V. Erspamer (Ed.), 5‐Hydroxytryptamine and related Indolealkylamines. Handbook of experimental pharmacology/Handbuch der experimentellen Pharmakologie (Vol. 19). Springer. https://doi.org/10.1007/978-3-642-85467-5_11
Caroff, S. N., Aggarwal, S., & Yonan, C. (2018). Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review. Journal of Comparative Effectiveness Research, 7(2), 135–148. https://doi.org/10.2217/cer-2017-0065
Cepeda, C., Murphy, K. P., Parent, M., & Levine, M. S. (2014). The role of dopamine in Huntington's disease. Progress in Brain Research, 211, 235–254. https://doi.org/10.1016/B978-0-444-63425-2.00010-6
Chan, O. L., & Webster, R. A. (1971). Effect of tetrabenazine and alpha‐methyl‐m‐tyrosine on exploratory activity and brain catecholamines in rats. British Journal of Pharmacology, 41(4), 691–699. https://doi.org/10.1111/j.1476-5381.1971.tb07077.x
Chen, J. J., Ondo, W. G., Dashtipour, K., & Swope, D. M. (2012). Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clinical Therapeutics, 34(7), 1487–1504. https://doi.org/10.1016/j.clinthera.2012.06.010
Chen, J. Y., Wang, E. A., Cepeda, C., & Levine, M. S. (2013). Dopamine imbalance in Huntington's disease: A mechanism for the lack of behavioral flexibility. Frontiers in Neuroscience, 7, 114. https://doi.org/10.3389/fnins.2013.00114
Curtis, M. J., Alexander, S. P. H., Cirino, G., George, C. H., Kendall, D. A., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Patel, H. H., Sobey, C. G., Stanford, S. C., Stanley, P., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ahluwalia, A. (2022). Planning experiments: Updated guidance on experimental design and analysis and their reporting III. British Journal of Pharmacology, 179(15), 3907–3913. Portico. https://doi.org/10.1111/bph.15868
Darchen, F., Scherman, D., & Henry, J. P. (1989). Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry, 28(4), 1692–1697. https://doi.org/10.1021/bi00430a040
de Tommaso, M., Serpino, C., & Sciruicchio, V. (2011). Management of Huntington's disease: Role of tetrabenazine. Therapeutics and Clinical Risk Management, 7, 123–129. https://doi.org/10.2147/TCRM.S17152
Di Chiara, G., Tanda, G. L., Frau, R., & Carboni, E. (1992). Heterologous monoamine reuptake: Lack of transmitter specificity of neuron‐specific carriers. Neurochemistry International, 20(Suppl), 231S–235S. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1365432
Erickson, J. D., & Varoqui, H. (2000). Molecular analysis of vesicular amine transporter function and targeting to secretory organelles. The FASEB Journal, 14(15), 2450–2458. https://doi.org/10.1096/fj.00-0206rev
Faul, F., Erdfelder, E., Buchner, A., & Lang, A. G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 41(4), 1149–1160. https://doi.org/10.3758/BRM.41.4.1149
Fitoussi, A., Dellu‐Hagedorn, F., & De Deurwaerdere, P. (2013). Monoamines tissue content analysis reveals restricted and site‐specific correlations in brain regions involved in cognition. Neuroscience, 255, 233–245. https://doi.org/10.1016/j.neuroscience.2013.09.059
Gallo, F. T., Zanoni Saad, M. B., Silva, A., Morici, J. F., Miranda, M., Anderson, M. C., Weisstaub, N. V., & Bekinschtein, P. (2022). Dopamine modulates adaptive forgetting in medial prefrontal cortex. The Journal of Neuroscience, 42(34), 6620–6636. https://doi.org/10.1523/JNEUROSCI.0740-21.2022
Gorska, A. M., & Golembiowska, K. (2015). The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA‐induced DA and 5‐HT release in the mouse striatum. Neurotoxicity Research, 27(3), 229–245. https://doi.org/10.1007/s12640-014-9501-0
Han, D. D., & Gu, H. H. (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 6, 6. https://doi.org/10.1186/1471-2210-6-6
Henry, J. P., Botton, D., Sagne, C., Isambert, M. F., Desnos, C., Blanchard, V., Raisman‐Vozari, R., Krejci, E., Massoulie, J., & Gasnier, B. (1994). Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. The Journal of Experimental Biology, 196, 251–262. https://doi.org/10.1242/jeb.196.1.251
Hersey, M., Hashemi, P., & Reagan, L. P. (2022). Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link? The European Journal of Neuroscience, 55(9–10), 2895–2911. https://doi.org/10.1111/ejn.15392
Jankovic, J. (1982). Treatment of hyperkinetic movement‐disorders with tetrabenazine—A double‐blind crossover study. Annals of Neurology, 11(1), 41–47. https://doi.org/10.1002/ana.410110108
Jastrzebska‐Wiesek, M., Wesolowska, A., Kolaczkowski, M., Varney, M. A., Newman‐Tancredi, A., & Depoortere, R. (2022). The selective 5‐HT 1A receptor agonist, NLX‐112, overcomes tetrabenazine‐induced catalepsy and depression‐like behavior in the rat. Behavioural Pharmacology, 33(5), 333–341. https://doi.org/10.1097/FBP.0000000000000681
Jentsch, J. D., Tran, A., Le, D., Youngren, K. D., & Roth, R. H. (1997). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical‐dependent cognition in the rat. Neuropsychopharmacology, 17(2), 92–99. https://doi.org/10.1016/S0893-133X(97)00034-1
John, C. E., & Jones, S. R. (2006). Exocytotic release of dopamine in ventral tegmental area slices from C57BL/6 and dopamine transporter knockout mice. Neurochemistry International, 49(8), 737–745. https://doi.org/10.1016/j.neuint.2006.06.004
Koenigs, M., & Grafman, J. (2009). The functional neuroanatomy of depression: Distinct roles for ventromedial and dorsolateral prefrontal cortex. Behavioural Brain Research, 201(2), 239–243. https://doi.org/10.1016/j.bbr.2009.03.004
Lakatos, M., Baranyi, M., Eross, L., Nardai, S., Torok, T. L., Sperlagh, B., & Vizi, E. S. (2020). Roles played by the Na+/Ca2+ exchanger and hypothermia in the prevention of ischemia‐induced carrier‐mediated efflux of catecholamines into the extracellular space: Implications for stroke therapy. Neurochemical Research, 45(1), 16–33. https://doi.org/10.1007/s11064-019-02842-0
Li, Y., Simmler, L. D., Van Zessen, R., Flakowski, J., Wan, J. X., Deng, F., Li, Y. L., Nautiyal, K. M., Pascoli, V., & Luscher, C. (2021). Synaptic mechanism underlying serotonin modulation of transition to cocaine addiction. Science, 373(6560), 1252–1256. https://doi.org/10.1126/science.abi9086
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., … Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611–3616. Portico. https://doi.org/10.1111/bph.15178
Margolis, R. L. (2014). Tetrabenazine, depression and suicide: Good news. Journal of Huntington's Disease, 3(2), 137–138. https://doi.org/10.3233/JHD-140107
Mathur, B. N., & Lovinger, D. M. (2012). Serotonergic action on dorsal striatal function. Parkinsonism & Related Disorders, 18, S129–S131. https://doi.org/10.1016/s1353-8020(11)70040-2
Metzger, R. R., Brown, J. M., Sandoval, V., Rau, K. S., Elwan, M. A., Miller, G. W., Hanson, G. R., & Fleckenstein, A. E. (2002). Inhibitory effect of reserpine on dopamine transporter function. European Journal of Pharmacology, 456(1–3), 39–43. https://doi.org/10.1016/s0014-2999(02)02647-x
Meyer, A. C., Horton, D. B., Neugebauer, N. M., Wooters, T. E., Nickell, J. R., Dwoskin, L. P., & Bardo, M. T. (2011). Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self‐administration. Neuropharmacology, 61(4), 849–856. https://doi.org/10.1016/j.neuropharm.2011.05.033
Miller, D. K., Crooks, P. A., Zheng, G., Grinevich, V. P., Norrholm, S. D., & Dwoskin, L. P. (2004). Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. The Journal of Pharmacology and Experimental Therapeutics, 310(3), 1035–1045. https://doi.org/10.1124/jpet.104.068098
Moll, G. H., Mehnert, C., Wicker, M., Bock, N., Rothenberger, A., Ruther, E., & Huether, G. (2000). Age‐associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Research. Developmental Brain Research, 119(2), 251–257. https://doi.org/10.1016/s0165-3806(99)00182-0
Morón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock‐out mouse lines. Journal of Neuroscience, 22(2), 389–395. https://doi.org/10.1523/Jneurosci.22-02-00389.2002
Nickell, J. R., Siripurapu, K. B., Vartak, A., Crooks, P. A., & Dwoskin, L. P. (2014). The vesicular monoamine transporter‐2: An important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Advances in Pharmacology, 69, 71–106. https://doi.org/10.1016/B978-0-12-420118-7.00002-0
Pearson, S. J., & Reynolds, G. P. (1988). Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology, 27(7), 717–719. https://doi.org/10.1016/0028-3908(88)90080-9
Percie du Sert, N., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Hurst, V., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Wurbel, H. (2020). Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biology, 18(7), e3000411. https://doi.org/10.1371/journal.pbio.3000411
Raiteri, M., Angelini, F., & Levi, G. (1974). A simple apparatus for studying the release of neurotransmitters from synaptosomes. European Journal of Pharmacology, 25(3), 411–414. https://doi.org/10.1016/0014-2999(74)90272-6
Ricciardi, L., Pringsheim, T., Barnes, T. R. E., Martino, D., Gardner, D., Remington, G., Addington, D., Morgante, F., Poole, N., Carson, A., & Edwards, M. (2019). Treatment recommendations for tardive dyskinesia. Canadian Journal of Psychiatry, 64(6), 388–399. https://doi.org/10.1177/0706743719828968
Rice, M. E., & Cragg, S. J. (2008). Dopamine spillover after quantal release: Rethinking dopamine transmission in the nigrostriatal pathway. Brain Research Reviews, 58(2), 303–313. https://doi.org/10.1016/j.brainresrev.2008.02.004
Robertson, S. D., Matthies, H. J., & Galli, A. (2009). A closer look at amphetamine‐induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Molecular Neurobiology, 39(2), 73–80. https://doi.org/10.1007/s12035-009-8053-4
Roman, V., Kedves, R., Kelemen, K., Nemethy, Z., Sperlagh, B., Lendvai, B., & Vizi, E. S. (2021). Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter‐mediated nonquantal dopamine release. Physiological Reports, 9(21), e15088. https://doi.org/10.14814/phy2.15088
Ross, S. B., & Renyi, A. L. (1966). In vitro inhibition of noradrenaline‐3H uptake by reserpine and tetrabenazine in mouse cerebral cortex tissues. Acta Pharmacologica et Toxicologica (Copenh), 24(1), 73–88. https://doi.org/10.1111/j.1600-0773.1966.tb00370.x
Santha, E., Sperlagh, B., Zelles, T., Zsilla, G., Toth, P. T., Lendvai, B., Baranyi, M., & Vizi, E. S. (2000). Multiple cellular mechanisms mediate the effect of lobeline on the release of norepinephrine. The Journal of Pharmacology and Experimental Therapeutics, 294(1), 302–307. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10871326
Schwarz, L. A., & Luo, L. (2015). Organization of the locus coeruleus‐norepinephrine system. Current Biology, 25(21), R1051–R1056. https://doi.org/10.1016/j.cub.2015.09.039
Spokes, E. G. (1980). Neurochemical alterations in Huntington's chorea: A study of post‐mortem brain tissue. Brain, 103(1), 179–210. https://doi.org/10.1093/brain/103.1.179
Steinbusch, H. W. (1981). Distribution of serotonin‐immunoreactivity in the central nervous system of the rat‐cell bodies and terminals. Neuroscience, 6(4), 557–618. https://doi.org/10.1016/0306-4522(81)90146-9
Sudhof, T. C. (2012). The presynaptic active zone. Neuron, 75(1), 11–25. https://doi.org/10.1016/j.neuron.2012.06.012
Vizi, E. S., Harsing, L. G. Jr., Zimanvi, I., & Gaal, G. (1985). Release and turnover of noradrenaline in isolated median eminence: Lack of negative feedback modulation. Neuroscience, 16(4), 907–916. https://doi.org/10.1016/0306-4522(85)90105-8
Vizi, E. S., Ono, K., Adam‐Vizi, V., Duncalf, D., & Foldes, F. F. (1984). Presynaptic inhibitory effect of Met‐enkephalin on [14C] acetylcholine release from the myenteric plexus and its interaction with muscarinic negative feedback inhibition. The Journal of Pharmacology and Experimental Therapeutics, 230(2), 493–499. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6747844
Vizi, E. S., Somogyi, G. T., Nagashima, H., Duncalf, D., Chaudhry, I. A., Kobayashi, O., Goldiner, P. L., & Foldes, F. F. (1987). Tubocurarine and pancuronium inhibit evoked release of acetylcholine from the mouse hemidiaphragm preparation. British Journal of Anaesthesia, 59(2), 226–231. https://doi.org/10.1093/bja/59.2.226
Vizi, E. S., Zsilla, G., Caron, M. G., & Kiss, J. P. (2004). Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock‐out mice: Implications for the action of selective serotonin reuptake inhibitors. The Journal of Neuroscience, 24(36), 7888–7894. https://doi.org/10.1523/JNEUROSCI.1506-04.2004
Volz, T. J., Hanson, G. R., & Fleckenstein, A. E. (2006). Kinetic analysis of developmental changes in vesicular monoamine transporter‐2 function. Synapse, 60(6), 474–477. https://doi.org/10.1002/syn.20321
Wang, H., Chen, X., Li, Y., Tang, T. S., & Bezprozvanny, I. (2010). Tetrabenazine is neuroprotective in Huntington's disease mice. Molecular Neurodegeneration, 5, 18. https://doi.org/10.1186/1750-1326-5-18
Williams, G. V., & Goldman‐Rakic, P. S. (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376(6541), 572–575. https://doi.org/10.1038/376572a0
Zsilla, G., Hegyi, D. E., Baranyi, M., & Vizi, E. S. (2018). 3,4‐Methylenedioxymethamphetamine, mephedrone, and beta‐phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake. European Journal of Pharmacology, 837, 72–80. https://doi.org/10.1016/j.ejphar.2018.08.037